Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients

Table 4 Characteristics of patients undergoing rescue therapy with successful and failed eradication, n (%)

Characteristic	Total, n = 130	VA success, n = 116	VA failure, n = 14	P value
Age in years	65.1 ± 3.6	65.0 ± 3.6	66.3 ± 3.3	0.180
Range	60-76	60-76	60-72
Sex as M/F	60/70	53/63	7/7	0.780
Weight in kg	65.8 ± 10.8	65.4 ± 10.4	68.8 ± 13.6	0.390
BMI in kg/m2	23.7 ± 2.9	23.6 ± 2.8	24.7 ± 4.0	0.320
Cigarette smoking	15 (11.5)	11 (9.5)	4 (28.6)	0.058
Alcohol drinking	27 (20.8)	24 (20.7)	3 (21.4)	1.000
Family history of gastric cancer	15 (11.5)	12 (10.3)	3 (21.4)	0.210
Endoscopy diagnosis
Gastritis	97 (77.2)	90 (77.6)	7 (50.0)	0.045a
CSG	32 (24.6)	30 (25.9)	2 (14.3)	0.520
CAG	65 (50.0)	60 (51.7)	5 (35.7)	0.400
Peptic ulcer	27 (20.8)	21 (18.1)	6 (42.8)	0.070
Gastric ulcer	11 (4.4)	7 (6.0)	4 (28.6)	0.018a
Duodenal ulcer	16 (6.4)	14 (12.1)	2 (14.3)	0.680
Complex (gastric and duodenal) ulcer	0	0	0	1.000
Gastric cancer	1 (0.8)	0	1 (7.1)	0.110
MALToma	0	0	0	1.000
Gastric hyperplastic polyp	5 (3.8)	5 (4.3)	0	1.000
Combined diseases	1.8 ± 1.4	1.7 ± 1.3	2.1 ± 2.0	0.540
0	26 (20.0)	24 (20.7)	2 (14.3)	0.740
1	34 (26.1)	28 (24.1)	6 (42.8)	0.190
2	35 (26.9)	34 (29.3)	1 (7.1)	0.110
≥ 3	35 (16.9)	30 (25.9)	5 (35.7)	0.520
Combined medicine	1.5 ± 1.7	1.5 ± 1.7	1.9 ± 2.4	0.490
0	45 (34.6)	40 (34.5)	5 (35.7)	1.000
1	36 (27.7)	33 (28.4)	3 (21.4)	0.760
2	17 (13.1)	15 (12.9)	2 (14.3)	1.000
≥ 3	32 (24.6)	28 (24.1)	4 (28.6)	0.750
Comorbidity
Hypertension	49 (37.7)	43 (37.1)	6 (42.8)	0.770
Diabetes mellitus	20 (15.4)	17 (14.7)	3 (21.4)	0.450
Hyperlipidemia	33 (25.4)	29 (25.0)	4 (28.6)	0.750
Heart disease	15 (11.5)	13 (11.2)	2 (14.3)	0.660
Lung disease	5 (3.8)	5 (4.3)	0	1.000
Liver disease	12 (9.2)	9 (7.8)	3 (21.4)	0.120
Renal disease	7 (5.4)	7 (6.0)	0	1.000
Cerebrovascular disease	7 (5.4)	7 (6.0)	0	1.000
Autoimmune disease	9 (6.9)	9 (7.8)	0	0.600
Hypersensitivity disease	4 (3.1)	4 (3.4)	0	1.000
Malignant tumor	19 (14.6)	17 (14.7)	2 (14.3)	1.000
Compliance	128 (98.5)	114 (98.3)	14 (100)	1.000
Adverse events	13 (10.0); 95%CI: 4.8%-15.2%	13 (11.2)	0	0.360
Eradication rate	89.2% (116/130); 95%CI: 83.9-94.6%

^aP < 0.05.

Data are mean ± SD unless otherwise indicated. Cigarette smoking was defined by consumption of > 5 cigarettes a day or > 1 cigarette pack/week consumed in the past 6 months. A family history of gastric cancer was defined as a gastric cancer diagnosis in a first-degree relative (such as a parent, sibling, or child). Alcohol drinking was defined by > 50 g of alcohol/day consumed in the past 6 months. Compliance was defined by > 80% of tablets taken as instructed. BMI: Body mass index; CSG: Chronic superficial gastritis; CAG: Chronic astrophic gastritis; F: Female; M: Male; MALToma: Mucosa-associated lymphoid tissue lymphoma; VA: Vonaprazan-amoxicillin.